withdrawn drugs database abilify

There was no substantial difference between treatment groups in delaying time to recurrence of depressive mood episodes.An examination of subgroups did not reveal any clear evidence of differential responsiveness on the basis of age, sex, or race.Abilify Maintena (aripiprazole) pre-filled dual chamber syringe for extended-release injectable suspension in single-use syringes is available in 300-mg or 400-mg strength syringes. Both doses of Abilify were superior to placebo in the PANSS total score (Study 6 in Table 26), the primary outcome measure of the study. Other compulsive urges, reported less frequently, include: sexual urges, shopping, eating or binge eating, and other impulsive or compulsive behaviors. In arriving at a diagnosis, it is important to exclude cases where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Over 75% of these subjects were under 13 years of age.Efficacy was evaluated using two assessment scales: the Aberrant Behavior Checklist (ABC) and the Clinical Global Impression-Improvement (CGI-I) scale. In addition, delayed sexual maturation was observed in males. Ratings for the TTS are made along 5 different dimensions on a scale of 0 to 5 for motor and vocal tics each. Advise pregnant women of potential fetal risk.The background risk of major birth defects and miscarriage for the indicated population are unknown. Inject full syringe contents immediately following reconstitution. The price of innovation: new estimates of drug development costsTiming of new black box warnings and withdrawals for prescription medicationsHERG, a primary human ventricular target of the nonsedating antihistamine terfenadineTrial watch: phase III and submission failures: 2007–2010Trial watch: phase II and phase III attrition rates 2011–2012Risk assessment and mitigation strategies for reactive metabolites in drug discovery and developmentTrends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998–2005Adverse drug reactions: definitions, diagnosis, and managementIdiosyncratic drug-induced liver injury: an overviewIdiosyncratic toxicity: a convergence of risk factorsPhenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sexCell based approaches for evaluation of drug-induced liver injuryDelays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysisNew active substances authorized in the United Kingdom between 1972 and 1994Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002: the importance of reporting suspected reactionsDrugBank: a knowledgebase for drugs, drug actions and drug targetse-Drug3D: 3D structure collections dedicated to drug repurposing and fragment-based drug designProTox: a web server for the in silico prediction of rodent oral toxicityThe Comparative Toxicogenomics Database's 10th year anniversary: update 2015Influence of search parameters and criteria on compound selection, promiscuity, and pan assay interference characteristicsThe RCSB Protein Data Bank: views of structural biology for basic and applied research and educationTherapeutic target database update 2014: a resource for targeted therapeuticsLarge-scale prediction and testing of drug activity on side-effect targetsThe ConsensusPathDB interaction database: 2013 updatedbSNP: a database of single nucleotide polymorphismsThe BioMart community portal: an innovative alternative to large, centralized data repositoriesUniProt Knowledgebase: a hub of integrated protein dataPredicting functional effect of human missense mutations using PolyPhen-2Data, information, knowledge and principle: back to metabolism in KEGGEffect of sibutramine on cardiovascular outcomes in overweight and obese subjectsCytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomesEffect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjectsPharmacogenetics of drugs withdrawn from the market© The Author(s) 2015.